辉瑞制药与三生制药于2025年5月19日达成两项重要合作:一是关于PD-1/VEGF双抗(SSGJ-707)的全球许可协议,二是辉瑞可能认购三生制药价值1亿美元的股票。具体分析如下:1. PD-1/VEGF双抗许可协议核心条款授权范围:辉瑞获得SSGJ-707在全球(除中国内地)的独家开发、生产和商业化权益,三生制药保留中国内地的权益,辉瑞可通过额外付款获得中国商业化选择权。支付条款:首付款:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.